GlassScriptPhysician profile
Rachel Williams
NPI 1114523263
$2,437.78
in general payments reported to CMS, 2019-2025
29 companies · $826 in 2025
The $826 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $275 · 2023: $578 · 2024: $615 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $336.64 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $247.15 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $209.12 | 2021-2024 | Jornay Pm |
| Exact Sciences Corporation | $181.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $126.50 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $125.98 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.35 | 2022-2023 | |
| Amgen INC. | $91.57 | 2023-2025 | Otezla, Repatha, Repatha |
| Collegium Pharmaceutical, INC. | $87.03 | 2025 | Jornay Pm |
| Novo Nordisk INC | $85.24 | 2022-2024 | |
| Tris Pharma INC | $78.89 | 2023-2025 | Onyda Xr, Quillivant, Dyanavel Xr |
| Paratek Pharmaceuticals, INC. | $69.05 | 2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.78 | 2023-2025 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $63.50 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Dexcom, INC. | $61.11 | 2022-2025 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $59.22 | 2023-2025 | |
| Ascensia Diabetes Care US INC. | $54.19 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $53.00 | 2023-2024 | Rexulti |
| Abbott Laboratories | $48.60 | 2024-2025 | Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $45.37 | 2023 | |
| Xeris Pharmaceuticals, INC. | $41.68 | 2022-2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $34.85 | 2025 | Auvelity |
| Lundbeck LLC | $26.32 | 2025 | Rexulti |
| Medtronic, INC. | $24.71 | 2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $23.93 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Biohaven Pharmaceutical Holding Company LTD. | $19.79 | 2022 | |
| Merck Sharp & Dohme LLC | $19.02 | 2023 | Verquvo, Steglatro |
| Pfizer INC. | $18.67 | 2025 | |
| Noven Therapeutics, LLC | $15.58 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.